|
|
|
|
A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21WAF1/CIP1) Degradation
|
|
|
|
|
|
|
|
نویسنده
|
esteve-puig r. ,gil r. ,gonzález-sánchez e. ,bech-serra j.j. ,grueso j. ,hernández-losa j. ,moliné t. ,canals f. ,ferrer b. ,cortés j. ,bastian b. ,ramón y cajal s. ,martín-caballero j. ,flores j.m. ,vivancos a. ,garcía-patos v. ,recio j.á.
|
|
منبع
|
plos genetics - 2014 - دوره : 10 - شماره : 10
|
|
چکیده
|
Exposure to ultraviolet (uv) radiation from sunlight accounts for 90% of the symptoms of premature skin aging and skin cancer. the tumor suppressor serine-threonine kinase lkb1 is mutated in peutz-jeghers syndrome and in a spectrum of epithelial cancers whose etiology suggests a cooperation with environmental insults. here we analyzed the role of lkb1 in a uv-dependent mouse skin cancer model and show that lkb1 haploinsufficiency is enough to impede uvb-induced dna damage repair,contributing to tumor development driven by aberrant growth factor signaling. we demonstrate that lkb1 and its downstream kinase nuak1 bind to cdkn1a. in response to uvb irradiation,lkb1 together with nuak1 phosphorylates cdkn1a regulating the dna damage response. upon uvb treatment,lkb1 or nuak1 deficiency results in cdkn1a accumulation,impaired dna repair and resistance to apoptosis. importantly,analysis of human tumor samples suggests that lkb1 mutational status could be a prognostic risk factor for uv-induced skin cancer. altogether,our results identify lkb1 as a dna damage sensor protein regulating skin uv-induced dna damage response. © 2014 esteve-puig et al.
|
|
|
|
|
آدرس
|
animal models and cancer laboratory,vall d'hebron research institute (vhir),hospital universitari vall d'hebron,barcelona,spain,department of dermatology,university of california san francisco,san francisco,ca, United States, animal models and cancer laboratory,vall d'hebron research institute (vhir),hospital universitari vall d'hebron,barcelona,spain,gene expression and cancer group vall d'hebron research institute of oncology (vhio),hospital universitari vall d'hebron,barcelona, Spain, animal models and cancer laboratory,vall d'hebron research institute (vhir),hospital universitari vall d'hebron,barcelona,spain,breast cancer group,centre for molecular medicine norway,oslo, Norway, proteomic laboratory medical oncology research program,vall d'hebron institute of oncology - vhio,hospital universitari vall d'hebron,barcelona, Spain, animal models and cancer laboratory,vall d'hebron research institute (vhir),hospital universitari vall d'hebron,barcelona,spain,experimental therapeutics group,hospital universitari vall d'hebron,barcelona, Spain, pathology department,hospital universitari vall d'hebron,barcelona, Spain, pathology department,hospital universitari vall d'hebron,barcelona, Spain, proteomic laboratory medical oncology research program,vall d'hebron institute of oncology - vhio,hospital universitari vall d'hebron,barcelona, Spain, pathology department,hospital universitari vall d'hebron,barcelona, Spain, clinical oncology program,vall d'hebron institute of oncology - vhio,barcelona, Spain, department of dermatology,university of california san francisco,san francisco,ca, United States, pathology department,hospital universitari vall d'hebron,barcelona, Spain, animal laboratory unit,barcelona biomedical research park (prbb),barcelona, Spain, surgery and medicine department,veterinary school,universidad complutense de madrid,madrid, Spain, cancer genomics group translational research program,vall d'hebron institute of oncology - vhio,hospital universitari vall d'hebron,barcelona, Spain, dermatology department,hospital universitari vall d'hebron,barcelona, Spain, animal models and cancer laboratory,vall d'hebron research institute (vhir),hospital universitari vall d'hebron,barcelona, Spain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|